LAVA <a href="https://laohu8.com/S/LENZ">Therapeutics</a> NV Appoints KPMG as New Auditor, Dismisses PwC Amid Remediated Internal Control Weaknesses
LAVA Therapeutics NV has announced a change in its certifying accountants, appointing KPMG LLP as its new independent registered public accounting firm for the fiscal year ending December 31, 2025. This decision follows the dismissal of PricewaterhouseCoopers Accountants N.V. (PwC), which had previously audited the company's financial statements for 2023 and 2024. PwC's reports during these years contained no adverse opinions or disclaimers. However, the company had identified material weaknesses in its internal controls over financial reporting, specifically related to inadequate general controls over information technology and segregation of duties. These issues were successfully remediated by the end of 2024, as reported in their Annual Report filed in March 2025. PwC had discussed these matters with LAVA's Audit Committee, and the company has permitted PwC to fully inform KPMG about these past issues.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LAVA Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-052460), on May 23, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。